Los Angeles Capital Management LLC Has $409,000 Stock Holdings in Altimmune, Inc. (NASDAQ:ALT)

Los Angeles Capital Management LLC trimmed its holdings in Altimmune, Inc. (NASDAQ:ALT) by 35.8% during the third quarter, Holdings Channel reports. The firm owned 66,537 shares of the company’s stock after selling 37,067 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Altimmune were worth $409,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Altimmune by 34.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 174,108 shares of the company’s stock valued at $1,069,000 after purchasing an additional 44,832 shares during the period. Creative Planning increased its position in Altimmune by 20.5% in the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after buying an additional 3,132 shares in the last quarter. Exchange Traded Concepts LLC increased its position in Altimmune by 74.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock valued at $1,331,000 after buying an additional 92,498 shares in the last quarter. PVG Asset Management Corp bought a new stake in Altimmune in the 2nd quarter valued at about $154,000. Finally, B. Riley Wealth Advisors Inc. bought a new stake in Altimmune in the 2nd quarter valued at about $138,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on the company. B. Riley reaffirmed a “buy” rating and issued a $20.00 target price on shares of Altimmune in a research report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research report on Thursday. Evercore ISI raised Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Finally, UBS Group assumed coverage on Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Altimmune has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Altimmune Stock Performance

Shares of ALT opened at $7.61 on Monday. The stock has a 50 day moving average price of $7.02 and a two-hundred day moving average price of $6.91. The firm has a market capitalization of $541.22 million, a P/E ratio of -4.91 and a beta of 0.09. Altimmune, Inc. has a 52 week low of $2.34 and a 52 week high of $14.84.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million for the quarter. During the same quarter in the previous year, the firm earned ($0.39) EPS. On average, equities analysts forecast that Altimmune, Inc. will post -1.36 earnings per share for the current year.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.